MarketCapExport financials
Seres Therapeutics (MCRB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Seres Therapeutics Income Statement 2025-2011 | MCRB
Brief overview of profit and loss at Seres Therapeutics
The comparison covers a five-year financial horizon. According to figures from Seres Therapeutics, revenue changed from $28.3 million to $126 million over five years. The cumulative result was +346.9%, corresponding to roughly 34.9% per year. Sales grew at a rate typical of a strong expansion phase.
EBITDA was −92.4 million dollars at the beginning and −102 million dollars at the end of the period (−10.1%). Changes in revenue did not translate into comparable EBITDA performance. Comparing the endpoints gives EBITDA margins of −327% and −80.5%. Higher profitability strengthens the quality of operating growth.
Comparing the endpoints shows a move from −$98.9 million to −$114 million. The loss widened and increased the financial risk.
The market value of the business moved from $250 million to $137 million, or −45.2%. The decline in value indicates softer investor confidence.
Conclusion
Signs of deterioration dominate the five-year picture. Key strengths include an improving EBITDA margin and a larger revenue base. The weaker side of the profile includes lower investor confidence, declining net profitability and limited operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Seres Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
62 M | 168 M | 6.85 M | 568 M | 734 M | 1.52 B | 189 M | 250 M | 421 M | 375 M | 544 M | - | - | - | - |
Shares |
8.86 M | 7.77 M | 6.4 M | 108 M | 91.7 M | 79.8 M | 56.6 M | 40.7 M | 40.4 M | 39.8 M | 23.5 M | - | - | - | - |
Historical Prices |
7 | 21.6 | 1.07 | 5.26 | 8 | 19 | 3.14 | 6.13 | 9.5 | 9.68 | 23.1 | - | - | - | - |
Net Income |
5.7 M | 136 K | -114 M | -250 M | -65.6 M | -89.1 M | -70.3 M | -98.9 M | -89.4 M | -91.6 M | -54.8 M | -16.7 M | -6.1 M | -3.13 M | - |
Revenue |
789 K | - | 126 M | 7.13 M | 145 M | 33.2 M | 34.5 M | 28.3 M | 32.1 M | 21.8 M | - | - | - | - | - |
Operating Income |
-94 M | -121 M | -195 M | -180 M | -64.5 M | -88.1 M | -71.9 M | -100 M | -91.4 M | -92.8 M | -54.9 M | -15.1 M | -6.05 M | - | - |
Interest Expense |
16.8 M | -14.1 M | 134 K | -705 K | -1.04 M | 981 K | 1.07 M | - | 1.59 M | 1.26 M | 83 K | - | - | - | - |
EBITDA |
-89.8 M | -116 M | -189 M | -173 M | -58.5 M | -81.6 M | -62.8 M | -92.4 M | -84.1 M | -88.6 M | -54.1 M | -13.5 M | -5.96 M | -3.01 M | - |
Operating Expenses |
94.8 M | 121 M | 195 M | 180 M | 209 M | 121 M | 105 M | 129 M | 123 M | 115 M | 54.9 M | - | - | - | - |
General and Administrative Expenses |
39.2 M | 53.2 M | 77.5 M | 70.3 M | 69.3 M | 30.8 M | 24.7 M | 32.6 M | 34 M | 32.6 M | 16.8 M | 4.36 M | 1.25 M | 956 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Seres Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
9.98 M | 9.71 M | 9.58 M | 124 K | 8.76 M | 8.74 M | 8.7 M | 265 K | 7.63 M | 7.58 M | 7.31 M | -121 M | 128 M | 128 M | 126 M | 5.7 M | 123 M | 92.3 M | 92.2 M | -183 M | 91.8 M | 91.7 M | 91.5 M | 3.87 M | 83.5 M | 73.3 M | 70.8 M | 4.51 M | 69.9 M | 45.1 M | 41 M | 44.1 M | 40.8 M | 40.7 M | 40.6 M | 29.9 M | 40.5 M | 40.4 M | 40.4 M | 171 K | 40.2 M | 39.6 M | 39.2 M | 5.24 M | 39 M | 8.64 M | 8.64 M | 6.89 M | 6.77 M | 6.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-16.3 M | 4.58 M | -19.9 M | -15.3 M | 8.2 M | -19.9 M | 32.7 M | -15.6 M | 88.8 M | -32.9 M | -40.1 M | -41.2 M | -47.9 M | 46.6 M | -71.2 M | -68.8 M | -60 M | -64.7 M | -56.6 M | -50 M | 68.2 M | -48.3 M | -35.5 M | -18.3 M | -30.3 M | -20.7 M | -19.9 M | -18.8 M | -16.4 M | -10.8 M | -24.3 M | -21.3 M | -21.9 M | -27.8 M | -27.9 M | -29 M | -6.94 M | -28 M | -25.5 M | -25.3 M | -18.7 M | -27.9 M | -19.7 M | -19.6 M | -14.6 M | -12.6 M | -7.97 M | -8.18 M | -4.16 M | -2.68 M | -1.69 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
593 K | 736 K | 358 K | 438 K | 351 K | - | - | - | - | - | - | -126 M | 310 K | 126 M | -522 K | 975 K | 3.44 M | 1.22 M | 1.49 M | 7.22 M | 127 M | 5.26 M | 4.65 M | 1.17 M | 80 K | 5.19 M | 5.46 M | 5.28 M | 4.84 M | 10.5 M | 6.62 M | 10.2 M | 8.68 M | 4.27 M | 3.77 M | 3.06 M | 23 M | 3.01 M | 3.02 M | 3.04 M | 13 M | 3 M | 2.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-16.2 M | -21.3 M | -20.9 M | -19.4 M | -22.5 M | -24.9 M | -27.2 M | -28.8 M | -29.2 M | -28.9 M | -34.4 M | -37 M | -44.6 M | 49.5 M | -70.6 M | -1.73 M | -59.1 M | -63.3 M | -55.8 M | -49.4 M | 68.4 M | -48.1 M | -35.3 M | -17.9 M | -30 M | -20.5 M | -19.7 M | -19.2 M | -17.2 M | -10.9 M | -24.6 M | -21.7 M | -22.2 M | -28.1 M | -28.3 M | -29.8 M | -7.31 M | -28.4 M | -25.9 M | -25.7 M | -19.1 M | -28.1 M | -19.9 M | -19.8 M | -14.6 M | -12.3 M | -8.17 M | -7.21 M | -3.58 M | -2.62 M | -1.67 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-280 K | 673 K | 669 K | 2.5 M | 2.84 M | 4.3 M | 7.12 M | 7.08 M | -22.5 M | 1.44 M | 505 K | 336 K | 999 K | -1.51 M | 310 K | -23 K | -33 K | -304 K | -345 K | -316 K | -35 K | -285 K | -409 K | -208 K | 345 K | 476 K | 368 K | - | - | - | - | - | 262 K | - | 347 K | 397 K | 379 K | -217 K | 416 K | 1.9 M | -312 K | -268 K | -56 K | 154 K | -59 K | 5 K | - | - | -61 K | -56 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-15.7 M | -20.6 M | -20.1 M | -18.4 M | -21.4 M | -23.8 M | -26.2 M | -27.8 M | -27.8 M | -27.5 M | -32.9 M | -35.4 M | -42.9 M | 51.1 M | -69.2 M | -104 K | -57.4 M | -61.6 M | -54.2 M | -47.9 M | 69.9 M | -46.7 M | -33.8 M | -16.4 M | -28.4 M | -18.9 M | -17.9 M | -17.4 M | -15.3 M | -9.03 M | -22.5 M | -19.7 M | -20.2 M | -26.2 M | -26.3 M | -27.9 M | -5.45 M | -26.7 M | -24.2 M | -24 M | -17.8 M | -27.3 M | -19.5 M | -19.5 M | -14.4 M | -12.2 M | -8.08 M | -7.21 M | -3.53 M | -2.58 M | -1.67 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
16.7 M | 22 M | 21.3 M | 19.8 M | 22.8 M | 24.9 M | 27.2 M | 28.8 M | 29.2 M | 28.9 M | 34.4 M | 37 M | 44.6 M | 76.9 M | 70 M | -4.42 M | 62.6 M | 64.5 M | 57.2 M | 56.7 M | 58.3 M | 53.4 M | 41 M | 35.5 M | 31.4 M | 26.6 M | 27.9 M | 26.8 M | 24.2 M | 23.5 M | 31.9 M | 32.3 M | 31.3 M | 32.7 M | 32.2 M | 32.8 M | 30.3 M | 31.4 M | 28.9 M | 28.7 M | 32.1 M | 31.1 M | 22.6 M | 19.8 M | 14.6 M | 12.3 M | 8.17 M | 7.21 M | 3.58 M | 2.62 M | 1.67 M | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
5.45 M | 7.06 M | 8.07 M | 7.54 M | 9.48 M | 10.3 M | 11.9 M | 12.5 M | 12.7 M | 13.1 M | 14.9 M | 14 M | 19.4 M | 28.1 M | 22.5 M | 13 M | 18.4 M | 20.3 M | 18.6 M | 20.5 M | 19.6 M | 17.5 M | 11.7 M | 10.6 M | 7.55 M | 6.49 M | 6.14 M | 5.78 M | 5.9 M | 5.57 M | 7.5 M | 7.53 M | 7.59 M | 8.7 M | 8.78 M | 8.79 M | 8.12 M | 8.37 M | 8.76 M | 8.45 M | 7.97 M | 8.97 M | 7.21 M | 5.89 M | 4.71 M | 3.56 M | 3.56 M | - | 1.11 M | 458 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Seres Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
